Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lanreotide Acetate

FDA-approved product (solution, subcutaneous), marketed as Lanreotide Acetate, Somatuline Depot.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lanreotide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Carcinoid syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Somatostatin and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA68.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lanreotide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lanreotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Lanreotide to Treat Polycystic Kidney Disease

    NCT01616927 · start 2012-06

    Registered record
    Registry ID
    NCT01616927
    Conditions
    Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Interventions
    Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2012-06
    Completion
    2017-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutosomal Dominant Polycystic Kidney Disease (ADPKD)
    InterventionLanreotide
    PhasePhase 3
    Registry statusUnknown

  • Acromegaly Combination Treatment Study

    NCT01538966 · start 2012-03-29

    Registered record
    Registry ID
    NCT01538966
    Conditions
    Acromegaly
    Interventions
    Pegvisomant; Octreotide LAR; Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2012-03-29
    Completion
    2022-05-20
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionPegvisomant; Octreotide LAR; Lanreotide
    PhaseNot applicable
    Registry statusTerminated

  • One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma

    NCT01471405 · start 2012-01

    Registered record
    Registry ID
    NCT01471405
    Conditions
    Acromegaly
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-08
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

    NCT01372007 · start 2011-07

    Registered record
    Registry ID
    NCT01372007
    Conditions
    Rectal Carcinoma
    Interventions
    Lanreotide Autogel 120mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-07
    Completion
    2014-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Carcinoma
    InterventionLanreotide Autogel 120mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients

    NCT01076803 · start 2009-10

    Registered record
    Registry ID
    NCT01076803
    Conditions
    Malignant Intestinal Obstruction
    Interventions
    Lanreotide (acetate)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    2013-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Intestinal Obstruction
    InterventionLanreotide (acetate)
    PhasePhase 2
    Registry statusCompleted

  • An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

    NCT00774930 · start 2009-05

    Registered record
    Registry ID
    NCT00774930
    Conditions
    Carcinoid Syndrome
    Interventions
    Lanreotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-05
    Completion
    2015-12
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoid Syndrome
    InterventionLanreotide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

    NCT00701363 · start 2008-10

    Registered record
    Registry ID
    NCT00701363
    Conditions
    Acromegaly
    Interventions
    Lanreotide Autogel 120 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-10
    Completion
    2013-05
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionLanreotide Autogel 120 mg
    PhasePhase 4
    Registry statusCompleted

  • Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

    NCT00652379 · start 2008-06

    Registered record
    Registry ID
    NCT00652379
    Conditions
    Acromegaly; Insulin Resistance; Impaired Glucose Tolerance
    Interventions
    Pegvisomant; Somatostatin analog (lanreotide or octreotide)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-06
    Completion
    2011-05
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly; Insulin Resistance; Impaired Glucose Tolerance
    InterventionPegvisomant; Somatostatin analog (lanreotide or octreotide)
    PhaseNot applicable
    Registry statusCompleted

  • Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study

    NCT00686348 · start 2008-05

    Registered record
    Registry ID
    NCT00686348
    Conditions
    Acromegaly
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-05
    Completion
    2015-11
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Open-Label Extension of LOCKCYST Trial

    NCT00771888 · start 2008-04

    Registered record
    Registry ID
    NCT00771888
    Conditions
    Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney; Autosomal Dominant
    Interventions
    lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2008-04
    Completion
    2009-08
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney +1 more
    Interventionlanreotide
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

    NCT00447499 · start 2007-04

    Registered record
    Registry ID
    NCT00447499
    Conditions
    Acromegaly
    Interventions
    Somatuline Autogel (lanreotide acetate); Home administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-04
    Completion
    2008-12
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionSomatuline Autogel (lanreotide acetate); Home administration
    PhasePhase 3
    Registry statusCompleted

  • GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma

    NCT00495846 · start 2007-04

    Registered record
    Registry ID
    NCT00495846
    Conditions
    Advanced Hepatocellular Carcinoma
    Interventions
    Octreotide-LAR, Lanreotide Autogel; Locoregional treatments
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-04
    Completion
    2008-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Hepatocellular Carcinoma
    InterventionOctreotide-LAR, Lanreotide Autogel; Locoregional treatments
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

    NCT00326469 · start 2006-05

    Registered record
    Registry ID
    NCT00326469
    Conditions
    Neuroendocrine Tumours
    Interventions
    lanreotide (Autogel formulation)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-05
    Completion
    2009-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumours
    Interventionlanreotide (Autogel formulation)
    PhasePhase 2
    Registry statusCompleted

  • Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

    NCT00288522 · start 2006-01

    Registered record
    Registry ID
    NCT00288522
    Conditions
    Thyroid-Associated Ophthalmopathy
    Interventions
    Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-01
    Completion
    2007-04
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid-Associated Ophthalmopathy
    InterventionLanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
    PhasePhase 2
    Registry statusTerminated

  • Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

    NCT00444873 · start 2005-01

    Registered record
    Registry ID
    NCT00444873
    Conditions
    Acromegaly
    Interventions
    lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-01
    Completion
    2008-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    Interventionlanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
    PhasePhase 3
    Registry statusCompleted